Please assess the completion status of the following clinical trial:

Trial Title: Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or Female, aged \>= 18 years~2. SARS-CoV-2-exposed subjects, as household members and/or contacts of COVID-19 patients (Group 1). In this group are included Health care professionals in contact with COVID-19 patients.~   or~3. COVID-19 patients, asymptomatic or paucisymptomatic in home situation who are not in treatment with any anti COVID-19 medication (Group 2)~4. Absence of any COVID-19 symptom in last week before randomization (fever \>37.5°C, cough, dyspnea) (only for group 1 subjects)~5. Paracetamol treatment is accepted only for group 2.~6. Participant is willing and able to give informed consent for participation in the study (either recorded during a telephonic interview or signed in person) and agrees with the study and its conduct.~Exclusion Criteria:~1. Reported anamnesis for:~   1. Intolerance or previous toxicity for hydroxychloroquine/chloroquine~  2. Bradycardia or reduction rhythm of heart with arrythmias~  3. Ischemic heart disease~  4. Retinopathy~  5. Congestive heart failure under/with use of diuretics~  6. Favism or glucose-6-phosphate dehydrogenase (G6PD) deficiency~  7. Diabetes type 1~  8. Major comorbidities like advanced chronic kidney disease or dialysis therapy, known history of ventricular arrhythmias, any oncologic/hematologic malignancy.~  9. Severe neurological and mental illness~2. Any other contraindication to take hydroxychloroquine~3. Already taking chloroquine, hydroxychloroquine or analogous during the past 3 weeks~4. Use of other antiviral agents in the last 3 weeks~5. Subject with a positive test for SARS-CoV-2 (for Group 1)~6. Pregnant or lactating~7. Current use of medications with known significant drug-drug interactions: digoxin, hypoglycemic agents, anticonvulsant, Cyclosporine, Phenylbutazone, drugs that inhibit CYP2D6~8. Known prolonged QT syndrome or current use of drugs with known QT prolongation~9. Participation in another clinical trial with any investigational agents within 30 days prior to study screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1: Hydroxychloroquine (Type: EXPERIMENTAL): A loading dose Hydroxychloroquine 400 mg twice daily at day 1, followed by a weekly dose of Hydroxychloroquine 200 mg twice daily on days 8, 15 and 22, covering a total of 1 month of treatment.
- Group 1: Observation (Type: NO_INTERVENTION): observation only
- Group 2: Hydroxycloroquine (Type: EXPERIMENTAL): A loading dose Hydroxychloroquine 400 mg twice daily at day 1 followed by 200 mg twice daily for a total of at least 5-7 days according to clinical evolution.
- Group 2: Observation (Type: NO_INTERVENTION): Observation only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues